🔎 Trials Near Me

Akèy › Timè nan sèvo › Texas › Dallas

Etid klinik pou Timè nan sèvo nan Dallas, TX

8 etid pou Timè nan sèvo ap chèche patisipan nan sit nan ak bò kote Dallas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Ap rekriteFaz 1/2
  • Baylor, Scott and White Research Institute, Dallas
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Ap rekriteFaz 2
  • UT Southwestern Medical Center/Harold C Simmons Comprehensive Cancer Center, Dallas
59 Months · Tout sèks · Mizajou Sep 15, 2026 · NCT05535166

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Ap rekriteFaz 1
  • Mary Crowley Cancer Research, Dallas
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

Ap rekriteFaz 1
  • Ut Southwestern Medical Center, Dallas
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT07139990

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

Ap rekriteFaz 1
  • Mary Crowley Cancer Research, Dallas
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06136884

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

Ap rekriteEtid obsèvasyon
  • UT Southwestern Simmons Cancer Center, Dallas
Tout laj · Tout sèks · Mizajou Jul 22, 2026 · NCT04427384

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Ap rekriteFaz 3
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Laj 18 ak plis · Tout sèks · Mizajou Oct 8, 2025 · NCT03418961

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Ap rekriteFaz 1/2
  • UT Southwestern Medical Center, Dallas
Laj 18 ak plis · Tout sèks · Mizajou Mar 26, 2025 · NCT01906385

Etid Timè nan sèvo nan lòt vil

Lòt etid nan Dallas

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.